Posted by Michael Wonder on 19 Dec 2017
Aerie Pharmaceuticals announces U.S. FDA approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the lowering of elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension
18 December 2017 - Product approved ahead of the Scheduled PDUFA date of 28 February 2018.
Aerie Pharmaceuticals today announced that the U.S. FDA has approved Rhopressa (netarsudil ophthalmic solution) 0.02% for the lowering of elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.
The FDA approval decision was made two months ahead of the scheduled PDUFA goal date of 28 February 2018.
